NRG
HZNP

Nemes Rush Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Nemes Rush Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15
Closed -$1.74K – 703
2023
Q3 		$1.74K Hold
15
– – ﹤0.01% 558
2023
Q2 		$1.54K Buy
+15
New +$1.58K ﹤0.01% 587

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Nemes Rush Group's HZNP Position: Q4 2023 in Review

Nemes Rush Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 15 shares — an estimated $1.74K sold.

Nemes Rush Group first reported a position in HZNP in Q2 2023 and held it in 2 quarters. The position peaked at $1.74K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Nemes Rush Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Nemes Rush Group sold 15 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.74K.
  • Nemes Rush Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 2 quarters.
  • Nemes Rush Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.74K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Nemes Rush Group's 13F filing for Q4 2023, filed 9 Feb 2024.